ELISA

The ELISA-based test has shown 98.8 percent sensitivity and 99.6 percent specificity for detecting SARS-CoV-2 specific IgG against two virus antigens.

The assay is the first SARS-CoV-2 neutralizing antibody test to receive Emergency Use Authorization from the FDA.

The Logan, Utah-based company's ELISA-based test is designed to detect immunoglobulin G against SARS-CoV-2 in human serum and plasma.

Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.

The test confirms the presence of antibodies directed to various gene products of HIV-1 and HIV-2 in human serum or plasma.

The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.

Researchers analyzed the performance of a dozen SARS-CoV-2 serology assays on samples from COVID-19 patients, patients with other disease, and pre-pandemic samples.

The three tests are designed to detect antibodies, including immunoglobulin G and M, against SARS-CoV-2 in human serum and plasma.